Oxurion Announces Results of the Extraordinary Shareholders’ Meeting of 22 May 2023
June 05, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, Belgium, Boston, MA, US – June 5, 2023 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
June 01, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – June 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care...
Oxurion to Participate in Upcoming Conferences
June 01, 2023 02:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – June 1, 2023 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next-generation standard of...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
May 31, 2023 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 22 convertible bonds in Oxurion resulting in a EUR 550,000 capital increase. This is part of Atlas Special...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
May 26, 2023 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC
May 22, 2023 13:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – May 22, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard of...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
May 19, 2023 13:00 ET
|
Oxurion NV
...
Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023
May 15, 2023 14:00 ET
|
Oxurion NV
Regulated Information Leuven, Belgium, Boston, MA, US – May 15, 2023 – 08.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS
May 12, 2023 13:02 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Atlas Special...